Related Experiment Video

Updated: Jul 7, 2026

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Challenges in pulmonary fibrosis: 7--Novel therapies and lung transplantation

T J Williams1, J W Wilson

  • 1Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Commercial Road, Melbourne 3004, Victoria, Australia.

Thorax
|March 1, 2008
PubMed

Insights

Pulmonary fibrosis treatments are limited, but research into mesenchymal stem cells and anti-inflammatory drugs shows promise. Lung transplantation offers survival benefits for eligible patients.

Area of Science:

  • Pulmonary Medicine
  • Regenerative Medicine
  • Immunology

Background:

  • Pulmonary fibrosis encompasses diseases lacking effective therapeutic options.
  • Clinical trials have yielded minimal improvements in patient outcomes.
  • Emerging research focuses on cellular mechanisms and progenitor cells.

Purpose of the Study:

  • To explore novel therapeutic strategies for pulmonary fibrosis.
  • To investigate the immunomodulatory potential of mesenchymal stem cells.
  • To evaluate the efficacy of anti-fibrotic and anti-inflammatory agents.

Main Methods:

  • Review of current clinical trials and preclinical studies.
  • Analysis of cellular mechanisms involving progenitor cells.
  • Assessment of emerging treatments including stem cell therapy and novel drug targets.

Main Results:

  • Mesenchymal stem cells demonstrate potential immunomodulatory roles.
  • Antagonist molecules targeting fibrogenic cytokines show promise.
  • Anti-inflammatory treatments, such as macrolide antibiotics, may offer benefits.
  • Lung transplantation provides a survival advantage, with 5-year survival rates around 40%.

Conclusions:

  • Current treatments for pulmonary fibrosis are inadequate.
  • Mesenchymal stem cell therapy and targeted molecular antagonism represent promising avenues.
  • Advancements in lung transplantation have improved survival rates.
  • Future therapeutic innovations are expected to enhance patient survival.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: